Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Overview

This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers including prostate cancer.

Full Title of Study: “PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Prostate Cancer: A Prospective Exploratory Biodistribution Study With Histopathology Validation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 9, 2024

Detailed Description

PRIMARY OBJECTIVE: I. To define the biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues of patients with prostate cancer. SECONDARY OBJECTIVES: I. To evaluate whether 68Ga-FAPi-46 and gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11) accumulation observed by positron emission tomography (PET) correlates with the amount of fibroblast activation protein (FAP) and prostate specific membrane antigen (PSMA) in excised cancer tissue, respectively. II. To assess the 68Ga-FAPI-46 biodistribution correlation with 68Ga-PSMA-11. OUTLINE: Patients receive 68Ga-FAPi-46 intravenously (IV) and undergo PET/computed tomography (CT) imaging over 20-50 minutes.

Interventions

  • Procedure: Computed Tomography
    • Undergo PET/CT imaging
  • Other: Gallium Ga 68 FAPi-46
    • Given IV
  • Procedure: Positron Emission Tomography
    • Undergo PET/CT imaging

Arms, Groups and Cohorts

  • Experimental: Basic Science (68Ga-FAPi-46 PET/CT)
    • Patients receive 68Ga-FAPi-46 IV and undergo PET/CT imaging over 20-50 minutes.

Clinical Trial Outcome Measures

Primary Measures

  • To define and document the biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues of patients with prostate cancer
    • Time Frame: 60 minutes after tracer injection
    • To quantify tumor tissue and normal background organs positron emission tomography (PET) tracer uptake by semi-quantitative analysis (unit/metrics = standardized uptake values [SUV], SUVmean and SUVmax.

Secondary Measures

  • To evaluate whether 68Ga-FAPi-46 accumulation observed by PET correlates with the amount of fibroblast activation protein (FAP) assessed by immunohistochemistry (IHC) in excised cancer tissue
    • Time Frame: Up to date of surgery (range 1-60 days)
    • 68Ga-FAPi-46 tumor SUVs will be correlated with FAP expression from surgically resected tumors. IHC will be scored with a semi-quantitative scoring system that accounts for staining intensity (0-2, where 0 is negative, 1 is weak, 2 is strong and eq. stands for equivocal). Correlations will be sought using least square regression analysis.
  • To assess the 68Ga-FAPI-46 biodistribution correlation with 68Ga-PSMA-11 PET imaging
    • Time Frame: 60 minutes after tracer injection
    • The 68Ga-PSMA-11 and 68Ga-FAPI-46 tracer biodistribution will be described by mean and maximum standardized uptake values (SUVmean and SUVmax) and tested for correlation.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients who underwent a 68Ga-PSMA-11 PET/CT scan within 3 months of enrollment – Patients who are scheduled to undergo surgical excision or biopsy of a prostate cancer primary, recurrent or metastatic lesion – Patients can provide written informed consent – Patients are able to remain still for duration of imaging procedure (up to one hour) Exclusion Criteria:

  • Patients with any new prostate therapy between the PSMA PET/CT and the FAP inhibitor (FAPI) PET/CT

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jonsson Comprehensive Cancer Center
  • Collaborator
    • Prostate Cancer Foundation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jeremie Calais, Principal Investigator, UCLA / Jonsson Comprehensive Cancer Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.